Embryonic lethality after combined inactivation of Fancd2 and Mlh1 in Mice

Cancer Research

Volumn 69, Issue 24, 2009, Pages 9431-9438

  Van De Vrugt, Henri J ^a   Eaton, Laura ^a   Newell, Amy Hanlon ^a   Al Dhalimy, Mushen ^a   Liskay, R Michael ^a   Olson, Susan B ^a   Grompe, Markus ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FANCONI ANEMIA GROUP D2 PROTEIN; PROTEIN MLH1; PSORALEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL IMMORTALIZATION; CHROMOSOME BREAKAGE; CHROMOSOME REARRANGEMENT; EMBRYO; FANCONI ANEMIA; FIBROBLAST; GENE INACTIVATION; GROWTH RETARDATION; KNOCKOUT MOUSE; LETHALITY; MISMATCH REPAIR; MOUSE; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; PUVA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CHROMOSOME ABERRATIONS; DNA MISMATCH REPAIR; EMBRYO, MAMMALIAN; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FEMALE; FETAL GROWTH RETARDATION; GENE SILENCING; INBREEDING; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOMYCIN; NUCLEAR PROTEINS; PREGNANCY;

EID: 73649134740     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2452     Document Type: Article

References (45)

1. Hoeijmakers JHJ. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
2. Van de Vrugt HJ, Grompe M. Fanconi anemia. In: Epstein CJ, Erickson RP, Wynshaw-Boris A, editors. Inborn errors of development. 2nd ed. New York: Oxford University Press; 2008, p. 1230-6.
3. Chirnomas D, Taniguchi T, De la Vega M, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006;5:952-61.
4. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
5. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15.
6. Pan X, Ye P, Yuan DS, Wang X, Bader JS, Boeke JD. A DNA integrity network in the yeast Saccharomyces cerevisiae. Cell 2006;124:1069-81.
7. Martin SA, Lord CJ, Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008;18:1-7.
8. Wimmer K, Etzer J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet 2008;124:105-22.
9. Grompe M, Van de Vrugt H. The Fanconi family adds a fraternal twin. Dev Cell 2007;12:661-2.
10. Smogorzewska A, Matsuoka S, Vinciguerra P, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 2007;129:289-301.
11. Peng M, Litman R, Xie J, Sharma S, Brosh RM, Jr., Cantor SB. The FANCJ/MutL interaction is required for correction of the cross-link response in FA-J cells. EMBO J 2007;26:3238-49.
12. Meetei AR, Sechi S, Wallisch M, et al. A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Mol Cell Biol 2003;23:3417-26.
13. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008;14:1291-5.
14. 6-methylguanine adducts. Mol Cell 2006;22:501-10.
15. Wang JYJ, Edelmann W. Mismatch repair proteins as sensors of alkylation DNA damage. Cancer Cell 2006;9:417-8.
16. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-6.
17. Claij N, Te Riele H. Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells. Oncogene 2004;23:260-6.
18. Houghtaling S, Timmers C, Noll M, et al. Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev 2003;17:2021-35.
19. Baker SM, Plug AW, Prolla TA, et al. Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over. Nat Genet 1996;13:336-42.
20. Houghtaling S, Granville L, Akkari Y, et al. Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Cancer Res 2005;65:85-91.
21. Houghtaling S, Newell A, Akkari Y, Taniguchi T, Olson S, Grompe M. Fancd2 functions in a double strand break repair pathway that is distinct from non-homologous end joining. Hum Mol Genet 2005;14:3027-33.
22. Timmers C, Taniguchi T, Hejna J, et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell 2001;7:241-8.
23. Buermeyer AB, Patten CWV, Baker SM, Liskay RM. The human MLH1 cDNA complements DNA mismatch repair defects in Mlh1-deficient mouse embryonic fibroblasts. Cancer Res 1999;59:538-41.
24. Akkari Y, Noll M, Bateman RL, et al. The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. Mol Genet Metab 2001;74:403-12.
25. Newell AH, Hemphill A, Akkari Y, Hejna J, Moses RE, Olson SB. Loss of homologous recombination or nonhomologous end joining leads to radial formation following DNA interstrand crosslink damage. Cytogenet Genome Res 2008;121:174-80.
26. Koomen M, Cheng NC, Van de Vrugt HJ, et al. Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 null mice. Hum Mol Genet 2002;11:273-81.
27. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 1997;11:1226-41.
28. Van de Vrugt HJ, Cheng NC, De Vries Y, et al. Cloning and characterization of murine Fanconi anemia group A gene: Fanca protein is expressed in lymphoid tissues, testis, and ovary. Mamm Genome 2000;11:326-31.
29. Van de Vrugt HJ, Koomen M, Berns MAD, et al. Characterization, expression and complex formation of the murine Fanconi anaemia gene product Fancg. Genes Cells 2002;7:333-42.
30. Paz M, Ladwa S, Champeil E, et al. Mapping DNA adducts of mitomycin C and decarbamoyl mitomycin C in cell lines using liquid chromatography/electrospray tandem mass spectrometry. Chem Res Toxicol 2008;21:2370-8.
31. Bissonnette L, Arnason JT, Smith ML. Real-time fluorescence-based detection of furanocoumarin photoadducts of DNA. Phytochem Anal 2008;19:342-7.
32. Wu Q, Vasquez KM. Human MLH1 protein participates in genomic damage checkpoint signaling in response to DNA interstrand crosslinks, while MSH2 functions in DNA repair. PLoS Genetics 2008;4:e1000189.
33. Gong J, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999;399:806-9.
34. Lan Z, Sever-Chroneos Z, Strobeck MW, et al. DNA damage invokes mismatch repair-dependent cyclin D1 attenuation and retinoblastoma signaling pathways to inhibit CDK2. J Biol Chem 2002;277:8372-81.
35. Stojic L, Mojas N, Cejka P, et al. Mismatch repairdependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev 2004;18:1331-44.
36. Kadyrov FA, Dzantiev L, Constatin N, Modrich P. Endonucleolytic function of MutLα in human mismatch repair. Cell 2006;126:297-308.
37. Schmutte C, Sadoff MM, Shim KS, Acharya S, Fishel R. The interaction of DNA mismatch repair proteins with human exonuclease I. J Biol Chem 2001;276:33011-8.
38. Yang W. Human MutLα the jack of all trades in MMR is also an endonuclease. Mut Res 2007;6:135-9.
39. Derheimer FA, Hicks JK, Paulsen MT, Canman CE, Ljungman M. Psoralen-induced DNA interstrand cross-links block transcription and induce p53 in an ataxiatelangiectasia and Rad3-related-dependent manner. Mol Pharmacol 2009;75:599-607.
40. Freie BW, Li X, Ciccone SLM, et al. Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. Blood 2004;102:4146-52.
41. Niedernhofer LJ, Lalai AS, Hoeijmakers JHJ. Fanconi anemia (cross)linked to DNA repair. Cell 2005;123:1191-8.
42. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007;8:735-48.
43. Elliott B, Jasin M. Repair of double-strand breaks by homologous recombination in mismatch repair-defective mammalian cells. Mol Cell Biol 2001;21:2671-82.
44. Shao C, Deng L, Chen Y, Kucherlapati R, Stambrook PJ, Tischfield JA. Mlh1 mediates tissue-specific regulation of mitotic recombination. Oncogene 2004;23:9017-24.
45. Sengupta S, Chakrabarti S, Roy A, Panda CK, Roychoudhury S. Inactivation of human mutL homolog 1 and mutS homolog 2 genes in head and neck squamous cell carcinoma tumors and leukoplakia samples by promoter hypermethylation and its relation with microsatellite instability phenotype. Cancer 2007;109:703-12.